<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Nitrofurantoin-induced pulmonary injury
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Nitrofurantoin-induced pulmonary injury
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Nitrofurantoin-induced pulmonary injury
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Justus de Zeeuw, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Adrian G Gillissen, MD, PhD, MSc
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kevin R Flaherty, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 30, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          Nitrofurantoin
         </a>
         is an antibacterial agent frequently used in the management of urinary tract infections (UTIs). This antimicrobial drug is generally used for treatment of acute cystitis and for prophylaxis in patients with recurrent UTIs. Pulmonary toxicity due to nitrofurantoin has two main presentations: an acute onset approximately nine days after a short course of therapy and a chronic onset developing after several months or years of nitrofurantoin therapy.
        </p>
        <p>
         The clinical manifestations, diagnosis, and treatment of
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         toxicity will be reviewed here. The evaluation and diagnosis of interstitial lung disease in general is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">
          "Approach to the adult with interstitial lung disease: Clinical evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The vast majority of patients (85 to 95 percent) who present with pulmonary reactions to
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         are women [
         <a href="#rid1">
          1,2
         </a>
         ]. This is related to the greater susceptibility of women to recurrent urinary tract infections, so that women are exposed to long-term nitrofurantoin more often than men.
        </p>
        <p>
         The median age among those presenting with the acute or chronic forms of the illness is approximately 60 and 70 years, respectively [
         <a href="#rid2">
          2,3
         </a>
         ]. A retrospective cohort study in adults aged 65 and older found an increased risk of lung injury with chronic, compared with acute, use of
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         (adjusted relative risk 1.53, 95% CI 1.04-2.24) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         The acute form of the illness is the most common pulmonary reaction to
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         , occurring in approximately 1 in 5000 patients after first exposure [
         <a href="#rid5">
          5,6
         </a>
         ]. In one study, among 66 patients with pulmonary reactions, 80 percent had an acute presentation and 20 percent had a subacute or chronic presentation [
         <a href="#rid3">
          3
         </a>
         ]. Respiratory impairment severe enough to require hospitalization occurs in approximately 1 of 750 long-term users [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         The prevalence of nitrofurantoin-induced pulmonary injury decreased from a high in the 1960s to a low in the 1980s. However, this condition is on the increase again, reflecting increased popularity as a urinary antiseptic [
         <a href="#rid8">
          8-13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PATHOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute and chronic pulmonary reactions to
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         have different histopathologic patterns [
         <a href="#rid3">
          3,14
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In acute pulmonary reactions, histopathologic examination of the lung typically reveals mild interstitial inflammation (sometimes with eosinophilia), reactive type II pneumocytes, focal hemorrhage, and (in some cases) eosinophils [
         <a href="#rid3">
          3
         </a>
         ]. Less common features include small organizing microthrombi, an alveolar exudate with macrophages and, rarely, granulomas.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In contrast, diffuse interstitial pneumonitis is observed in chronic reactions [
         <a href="#rid14">
          14-16
         </a>
         ], and some reports have noted vascular sclerosis, thickening of the alveolar septa, and interstitial inflammation [
         <a href="#rid3">
          3
         </a>
         ]. A pattern of organizing pneumonia (also known as bronchiolitis obliterans organizing pneumonia) has also been reported [
         <a href="#rid17">
          17-21
         </a>
         ], as have chronic eosinophilic pneumonia [
         <a href="#rid22">
          22
         </a>
         ], and desquamative interstitial pneumonia with accumulation of macrophages in the alveoli [
         <a href="#rid10">
          10,23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4360.html" rel="external">
          "Chronic eosinophilic pneumonia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The acute and chronic forms of lung injury result from different pathogenic mechanisms. The acute form has features of a hypersensitivity reaction (type I or III). By comparison, the chronic form may be either a cell-mediated or toxic response. In vitro studies suggest that toxic products produced by drug metabolites may cause injury in the presence of oxygen and lung microsomes. This mechanism of lung damage may be similar to that observed with the herbicide paraquat [
         <a href="#rid24">
          24,25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/337.html" rel="external">
          "Paraquat poisoning"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary reactions to
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         do not appear to be dose related, and can present with a range of symptoms. Concomitant hepatic toxicity has been described [
         <a href="#rid3">
          3,26-28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H283237806">
         <span class="h2">
          Acute hypersensitivity
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mean onset of symptoms of acute hypersensitivity pneumonitis due to
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         is 8.7 days after initiation of nitrofurantoin, based on a series of 66 patients [
         <a href="#rid3">
          3
         </a>
         ]. However, when symptoms develop after repeat exposure, the onset is much shorter (often within 24 hours) [
         <a href="#rid5">
          5,15
         </a>
         ].
        </p>
        <p>
         The most frequently reported symptoms are fever exceeding 37.9ºC (82 percent), dyspnea (60 percent), irritating cough (43 percent), and rash (20 percent) [
         <a href="#rid2">
          2,3
         </a>
         ]. Chest pain and cyanosis may also occur [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         Inspiratory crackles (especially over the basal lung fields) are heard in most patients [
         <a href="#rid3">
          3,5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4103509600">
         <span class="h2">
          Chronic pneumonitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptoms of chronic pulmonary reactions develop after several months (eg, six months to several years) of low dose treatment [
         <a href="#rid1">
          1,2,16
         </a>
         ]. The most frequently reported symptoms are dyspnea (73 percent), dry cough (63 percent), and fatigue (37 percent). Symptoms are usually less intense than in acute reactions [
         <a href="#rid3">
          3
         </a>
         ]. Fever is uncommon in patients with the chronic form of the disease [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Dry crackles are reported in patients with chronic reactions [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         For patients with drug-induced lupus or antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, skin rash (eg, palpable purpura) may be present [
         <a href="#rid30">
          30,31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3767245787">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evaluation of suspected
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         lung toxicity is designed to review the association of symptoms and signs with nitrofurantoin use, explore other exposures, exclude other diseases with a similar presentation, and assess the severity of respiratory impairment.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Laboratory findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with any patient being evaluated for new onset interstitial lung disease, initial laboratory testing is focused on assessing possible contributions from infection, heart failure, and rheumatic disease. The evaluation of acute and chronic presentations of
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         lung toxicity is similar, except for a greater focus on infection in acute presentations and a greater focus on rheumatic disease in patients with a gradual onset of symptoms.
        </p>
        <p>
         A complete blood count and differential is useful to look for eosinophilia and indirectly for evidence of infection. For acute presentations routine bacterial, atypical bacterial, and viral infections are high in the differential diagnosis. In addition to blood cultures, other testing may include serology for influenza, community respiratory viral infections, mycoplasma, and Legionnaire’s disease. A brain natriuretic peptide can help to exclude heart failure. (See
         <a class="medical medical_review" href="/z/d/html/7032.html" rel="external">
          "Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults"
         </a>
         .)
        </p>
        <p>
         Among patients with acute reactions, the most commonly reported laboratory findings are eosinophilia (69 to 83 percent), leukocytosis (34 to 52 percent), and an elevated erythrocyte sedimentation rate (over 50 mm/hour, 44 percent) [
         <a href="#rid2">
          2,3
         </a>
         ].
        </p>
        <p>
         By comparison, findings noted in the chronic group include elevated serum gamma globulins (80 percent), eosinophilia (44 percent), elevated serum transaminases (37 percent), and increased erythrocyte sedimentation rates [
         <a href="#rid2">
          2,3
         </a>
         ]. A variety of positive serologies have been reported, including antinuclear antibody [
         <a href="#rid32">
          32
         </a>
         ], antismooth muscle antibody [
         <a href="#rid32">
          32
         </a>
         ], and antineutrophil cytoplasmic antibody (ANCA; typically myeloperoxidase) [
         <a href="#rid3">
          3,10,31
         </a>
         ]. Positive antinuclear antibody was noted in 25 percent of acute cases and 60 percent of chronic cases in one study [
         <a href="#rid2">
          2,33
         </a>
         ]. In a separate report, positive rheumatoid factor tests were found in isolated patients in the acute and chronic groups, but were only assessed in a few patients [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1432856248">
         <span class="h2">
          Pulmonary function tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         The main role of pulmonary function testing (eg, spirometry, lung volumes, diffusing capacity for carbon monoxide, and six-minute walk test) is to assess the severity of respiratory impairment. Most patients exhibit some degree of pulmonary dysfunction on pulmonary function testing.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study, for example, all patients had a moderate impairment of the gas transfer factor (47 to 78 percent of the reference value) when examined within two weeks after admission to the hospital [
         <a href="#rid3">
          3
         </a>
         ]. No reduction in forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) or vital capacity was observed [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a second report, half of patients with chronic disease had a restrictive pattern of pulmonary dysfunction with reduced lung volumes [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         A conventional chest radiograph is frequently obtained to evaluate patients with complaints of dyspnea and cough, particularly when associated with crackles on physical examination and/or a decrease in pulse oxygen saturation. High resolution chest tomography (HRCT) is obtained to clarify the pattern and extent of abnormalities.
        </p>
        <p>
         Abnormalities are observed on chest radiograph in the vast majority of patients (
         <a class="graphic graphic_diagnosticimage graphicRef50491" href="/z/d/graphic/50491.html" rel="external">
          image 1
         </a>
         ). In one study, one-third of patients were noted to have diffuse parenchymal changes consisting of streaky or mottled shadowing located predominantly in the lower lung zones [
         <a href="#rid3">
          3
         </a>
         ]. Parenchymal changes were almost always bilateral. Pleural effusions, which were predominantly unilateral, were accompanied by parenchymal changes.
        </p>
        <p>
         In a separate study, all patients with chronic reactions had pulmonary parenchymal opacities on chest radiography [
         <a href="#rid2">
          2
         </a>
         ]. Pleural effusions are rare in patients with the chronic form of the disease.
        </p>
        <p>
         The CT findings of chronic nitrofurantoin-induced lung disease were evaluated in a retrospective review of 18 patients [
         <a href="#rid1">
          1
         </a>
         ]. Bilateral areas of ground glass attenuation with no dominant pattern of zonal distribution were the most common pattern. In contrast to patients with idiopathic pulmonary fibrosis, irregular linear opacities were uncommon. Honeycombing is rarely present [
         <a href="#rid9">
          9,34
         </a>
         ], and pleural effusions are uncommon [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Other patterns that are described in rare reports include chronic eosinophilic pneumonia and organizing pneumonia.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a case report, HRCT showed ground glass opacities with an upper lung zone peripheral pattern similar to chronic eosinophilic pneumonia (CEP), and lung biopsy confirmed CEP [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A small number of reports describe a late onset of imaging and histopathology findings consistent with organizing pneumonia [
         <a href="#rid17">
          17-20
         </a>
         ]. In these patients, the HRCT showed bilateral asymmetric areas of consolidation and patchy ground glass opacities [
         <a href="#rid17">
          17,19
         </a>
         ]. (See
         <a class="local">
          'Pathology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Bronchoalveolar lavage
         </span>
         <span class="headingEndMark">
          —
         </span>
         The main roles of bronchoalveolar lavage are to evaluate for eosinophilia and to exclude infection, alveolar hemorrhage, and lymphangitic carcinomatosis. (See
         <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">
          "Role of bronchoalveolar lavage in diagnosis of interstitial lung disease"
         </a>
         .)
        </p>
        <p>
         The results obtained with bronchoalveolar lavage (BAL) in patients with nitrofurantoin-induced pulmonary injury are nonspecific and include lymphocytosis, neutrophilia, and eosinophilia [
         <a href="#rid24">
          24,35-37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4154845367">
         <span class="h2">
          Lung biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lung biopsy is typically not necessary due to the high rate of improvement with drug withdrawal. In selected cases, especially when there is no substantial improvement after discontinuation of
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         and other diagnoses (eg, infection, heart failure) have been taken into consideration, a lung biopsy may be appropriate. Depending on availability, lung biopsy may be accomplished by transbronchial cryobiopsy or video-assisted thoracoscopic surgery [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">
          "Role of lung biopsy in the diagnosis of interstitial lung disease"
         </a>
         .)
        </p>
        <p>
         When obtained, lung biopsy of
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         pulmonary toxicity typically reveals interstitial inflammation (often eosinophilic) in acute disease, or nonspecific interstitial pneumonia in chronic disease [
         <a href="#rid1">
          1
         </a>
         ], although other patterns such as organizing pneumonia and chronic eosinophilic pneumonia have been reported. (See
         <a class="local">
          'Pathology'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H425459514">
         <span class="h2">
          Acute pneumonitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of acute lung toxicity from
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         is based on the presence of characteristic symptoms, duration of time between drug exposure and symptom onset, and response to drug discontinuation [
         <a href="#rid2">
          2,3
         </a>
         ]. Common alternative diagnoses to be excluded are heart failure, community acquired pneumonia (eg, bacterial, atypical, or viral), and exacerbations of asthma or chronic obstructive pulmonary disease (COPD). (See
         <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">
          "Approach to the adult with interstitial lung disease: Clinical evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         .)
        </p>
        <p>
         In the acute form, symptoms should improve within 24 to 48 hours after discontinuation of
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         therapy. Failure of resolution should lead to consideration of other diagnostic possibilities and additional testing. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3288685544">
         <span class="h2">
          Chronic lung toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic lung toxicity can usually be recognized by a compatible history of exposure to
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         , a restrictive pattern in lung function testing, and bilateral reticular and ground glass opacities on imaging studies. Infection, heart failure, rheumatic disease, and chronic hypersensitivity pneumonitis should be excluded. For patients with more severe respiratory impairment, bronchoscopy with bronchoalveolar lavage may be indicated to evaluate other possibilities, while awaiting response to drug discontinuation. It may take weeks to months for the symptoms and radiographic changes to regress after cessation of nitrofurantoin.
        </p>
        <p class="headingAnchor" id="H1387681412">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of acute
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         pulmonary toxicity includes infection, lymphangitic tumor, heart failure, acute eosinophilic pneumonia, acute hypersensitivity pneumonitis, and acute interstitial pneumonia. (See
         <a class="medical medical_review" href="/z/d/html/4374.html" rel="external">
          "Idiopathic acute eosinophilic pneumonia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4313.html" rel="external">
          "Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4369.html" rel="external">
          "Acute interstitial pneumonia (Hamman-Rich syndrome)"
         </a>
         .)
        </p>
        <p>
         The differential diagnosis of chronic
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         pulmonary toxicity includes the idiopathic interstitial pneumonias, chronic hypersensitivity pneumonitis, sarcoidosis, and rheumatic diseases with lung involvement. However, the presence of autoantibodies can be a manifestation of the reaction to nitrofurantoin and may not indicate a separate rheumatic disease. (See
         <a class="local">
          'Laboratory findings'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4677.html" rel="external">
          "Drug-induced lupus"
         </a>
         .)
        </p>
        <p>
         Depending on the severity of disease, degree of concern about infection, alveolar hemorrhage, or tumor, presence of extrapulmonary manifestations of rheumatic disease, bronchoscopy with bronchoalveolar lavage, and/or a transbronchial or surgical lung biopsy may be needed to evaluate alternative diagnoses [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">
          "Role of bronchoalveolar lavage in diagnosis of interstitial lung disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">
          "Role of lung biopsy in the diagnosis of interstitial lung disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Discontinuation of
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         therapy is the cornerstone of therapy for both acute and chronic presentations of nitrofurantoin lung toxicity. For patients with an acute presentation, regression of symptoms and radiographic abnormalities is generally rapid, over days to weeks [
         <a href="#rid2">
          2,3,14
         </a>
         ]. However, for chronic presentations, weeks to months may be required for full recovery. Rechallenge with nitrofurantoin is not advised due to the high likelihood of recurrence [
         <a href="#rid29">
          29,33,39
         </a>
         ].
        </p>
        <p>
         Oral glucocorticoids are sometimes given as a therapeutic measure [
         <a href="#rid1">
          1,3
         </a>
         ], but the benefit has never been proven. We typically do
         <strong>
          not
         </strong>
         use glucocorticoids for treatment of
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         lung toxicity, unless the patient has severe respiratory compromise, and only after infection has been carefully excluded. For patients with severe respiratory impairment (eg, dyspnea and hypoxemia at rest), a prednisone-equivalent dose of 0.5 to 1.0 mg/kg (up to 60 mg) per day is given with tapering as tolerated over several weeks to months.
        </p>
        <p>
         Individual case reports have demonstrated rapid improvement after initiation of glucocorticoids [
         <a href="#rid9">
          9,14,15,24,40
         </a>
         ], but resolution without glucocorticoids is common and even severe pulmonary toxicity may resolve without glucocorticoids [
         <a href="#rid21">
          21,40
         </a>
         ].
        </p>
        <p>
         Follow up is needed to ascertain whether other abnormalities, such as peripheral blood eosinophilia, elevated transaminases, and autoantibody positivity, have resolved.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognosis is good if the condition is recognized early and
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         is stopped [
         <a href="#rid14">
          14
         </a>
         ]. Most patients with an acute pulmonary reaction recover within 15 days [
         <a href="#rid3">
          3
         </a>
         ]. One study found that 47 percent of patients were symptom-free within one day, and 88 percent within three days [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Among patients with chronic reactions, recovery took from two weeks to three months, although mild fibrotic changes persisted in two-thirds of patients [
         <a href="#rid3">
          3
         </a>
         ]. Resolution of advanced-appearing interstitial disease on CT has been reported following discontinuation of the drug [
         <a href="#rid9">
          9,40
         </a>
         ].
        </p>
        <p>
         Despite the generally good prognosis, fatalities have been reported [
         <a href="#rid2">
          2,3,34,41-43
         </a>
         ]. As an example, among 392 nitrofurantoin-associated respiratory adverse effects reported to the Medicines and Healthcare products Regulatory Authority (MHRA) from 1963 to 2010, 11 had a fatal outcome [
         <a href="#rid43">
          43
         </a>
         ]. Additional cases of fatal nitrofurantoin-induced pulmonary injury have been described separately [
         <a href="#rid2">
          2,3,41,44
         </a>
         ]. Interactions with concomitant drugs, eg,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , may lead to irreversible fibrosis [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6718247">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – Nitrofurantoin-induced pulmonary toxicity has two main presentations (see
         <a class="local">
          'Clinical manifestations'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Acute reactions – Fever, dyspnea, and cough approximately nine days after starting therapy; rash is occasionally seen
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chronic toxicity – Insidious onset of dyspnea, dry cough, and fatigue in the absence of fever
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – Laboratory findings are generally nonspecific. Peripheral blood eosinophilia is common among patients with acute reactions. Chronic reactions can also be associated with elevations in serum transaminases and erythrocyte sedimentation rate. Imaging frequently shows diffuse opacities. Chronic disease is often associated with restriction on pulmonary function testing. (See
         <a class="local">
          'Evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Acute reactions – The diagnosis of an acute reaction to
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         can be established by the combination of exposure to nitrofurantoin, the characteristic time course and pattern of symptoms, and compatible laboratory tests. Prompt resolution following discontinuation of nitrofurantoin further supports the diagnosis. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chronic toxicity – The diagnosis of chronic pulmonary toxicity is based on the history of long-term
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         therapy, the absence of another explanation for the patient’s symptoms and radiographic abnormalities, and response to drug cessation. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Acute reactions – The differential diagnosis of acute
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         pulmonary toxicity includes infection, heart failure, acute eosinophilic pneumonia, acute hypersensitivity pneumonitis, acute idiopathic interstitial pneumonia, and less commonly lymphangitic tumor. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chronic toxicity – The differential diagnosis of chronic
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         pulmonary toxicity includes the idiopathic interstitial pneumonias, rheumatic diseases with lung involvement, chronic hypersensitivity pneumonitis, sarcoidosis, and alveolar hemorrhage. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">
          "Approach to the adult with interstitial lung disease: Clinical evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – Discontinuation of
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         is required for both acute and chronic presentations of nitrofurantoin lung toxicity because continued use is associated with progressive respiratory insufficiency. We do not typically use other treatments (eg, glucocorticoids or immunosuppressants) in the absence of severe respiratory compromise. Nitrofurantoin should not be reintroduced due to the high rate of recurrence. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with substantial respiratory insufficiency (eg, dyspnea and hypoxemia at rest), we suggest initiation of oral glucocorticoids (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ) after ruling out infectious etiologies. The usual dose is the equivalent of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         0.5 to 1.0 mg/kg (up to 60 mg) per day with tapering as tolerated over several weeks to months. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Generally, symptoms and signs of acute
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         lung toxicity improve within a few days, while chronic toxicity improves over weeks to months. Some patients have persistent radiographic abnormalities; rare cases are fatal. (See
         <a class="local">
          'Treatment'
         </a>
         above and
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24530256">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Jochen Schumacher, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Mendez JL, Nadrous HF, Hartman TE, Ryu JH. Chronic nitrofurantoin-induced lung disease. Mayo Clin Proc 2005; 80:1298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmberg L, Boman G. Pulmonary reactions to nitrofurantoin. 447 cases reported to the Swedish Adverse Drug Reaction Committee 1966-1976. Eur J Respir Dis 1981; 62:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sovijärvi AR, Lemola M, Stenius B, Idänpään-Heikkilä J. Nitrofurantoin-induced acute, subacute and chronic pulmonary reactions. Scand J Respir Dis 1977; 58:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santos JM, Batech M, Pelter MA, Deamer RL. Evaluation of the Risk of Nitrofurantoin Lung Injury and Its Efficacy in Diminished Kidney Function in Older Adults in a Large Integrated Healthcare System: A Matched Cohort Study. J Am Geriatr Soc 2016; 64:798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kabbara WK, Kordahi MC. Nitrofurantoin-induced pulmonary toxicity: A case report and review of the literature. J Infect Public Health 2015; 8:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huttner A, Verhaegh EM, Harbarth S, et al. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother 2015; 70:2456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jick SS, Jick H, Walker AM, Hunter JR. Hospitalizations for pulmonary reactions following nitrofurantoin use. Chest 1989; 96:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camus P, Fanton A, Bonniaud P, et al. Interstitial lung disease induced by drugs and radiation. Respiration 2004; 71:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viejo MA, Fernández Montes A, Montes JV, et al. [Rapid resolution of nitrofurantoin-induced interstitial lung disease]. Arch Bronconeumol 2009; 45:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hage P, El Hajje MJ. Nitrofurantoin-induced desquamative interstitial pneumonitis in a 7-year-old child. Pediatr Infect Dis J 2011; 30:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin DC, Bhally H. Nitrofurantoin-induced interstitial lung disease. N Z Med J 2007; 120:U2753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilkin T, Hale LS, Claiborne RA. Poor medication history plus slow symptom onset delays a diagnosis. JAAPA 2009; 22:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mrozek N, Delèvaux I, Legendre M, et al. [Nitrofurantoin-induced lung disease: about two cases]. Rev Med Interne 2008; 29:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson BW. Nitrofurantoin-induced interstitial pulmonary fibrosis. Presentation and outcome. Med J Aust 1983; 1:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hainer BL, White AA. Nitrofurantoin pulmonary toxicity. J Fam Pract 1981; 13:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenow EC 3rd, DeRemee RA, Dines DE. Chronic nitrofurantoin pulmonary reaction. Report of 5 cases. N Engl J Med 1968; 279:1258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cameron RJ, Kolbe J, Wilsher ML, Lambie N. Bronchiolitis obliterans organising pneumonia associated with the use of nitrofurantoin. Thorax 2000; 55:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dodd JD, Lee KS, Johkoh T, Müller NL. Drug-associated organizing pneumonia: high-resolution CT findings in 9 patients. J Thorac Imaging 2006; 21:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fenton ME, Kanthan R, Cockcroft DW. Nitrofurantoin-associated bronchiolitis obliterans organizing pneumonia: report of a case. Can Respir J 2008; 15:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanji Z, Su VC, Mainra R. Nitrofurantoin-induced pulmonary reaction involving respiratory symptoms: case report. Can J Hosp Pharm 2011; 64:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhullar S, Lele SM, Kraman S. Severe nitrofurantoin lung disease resolving without the use of steroids. J Postgrad Med 2007; 53:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martins RR, Marchiori E, Viana SL, et al. Chronic eosinophilic pneumonia secondary to long-term use of nitrofurantoin: high-resolution computed tomography findings. J Bras Pneumol 2008; 34:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bone RC, Wolfe J, Sobonya RE, et al. Desquamative interstitial pneumonia following long-term nitrofurantoin therapy. Am J Med 1976; 60:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lenci G, Müller-Quernheim J, Lorenz J, Ferlinz R. [Pulmonary toxicity caused by nitrofurantoin]. Pneumologie 1993; 47:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyd MR, Catignani GL, Sasame HA, et al. Acute pulmonary injury in rats by nitrofurantoin and modification by vitamin E, dietary fat, and oxygen. Am Rev Respir Dis 1979; 120:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peall AF, Hodges A. Concomitant pulmonary and hepatic toxicity secondary to nitrofurantoin: a case report. J Med Case Rep 2007; 1:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koulaouzidis A, Bhat S, Moschos J, et al. Nitrofurantoin-induced lung- and hepatotoxicity. Ann Hepatol 2007; 6:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carvalho de Matos A, Pais Macedo C, Afonso Mendes P, et al. Concomitant Nitrofurantoin-Induced Autoimmune Hepatitis and Interstitial Lung Disease. GE Port J Gastroenterol 2022; 29:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams EM, Triller DM. Recurrent acute nitrofurantoin-induced pulmonary toxicity. Pharmacotherapy 2006; 26:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murie J, Agarwal M. Sub-acute cutaneous lupus erythematosus following nitrofurantoin: causative or coincidental? Scott Med J 2014; 59:e21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal A, Agrawal A, Nathan K, Roy S. Rare adverse effect of a common drug: nitrofurantoin-induced ANCA-associated vasculitis. BMJ Case Rep 2015; 2015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schattner A, Von der Walde J, Kozak N, et al. Nitrofurantoin-induced immune-mediated lung and liver disease. Am J Med Sci 1999; 317:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmberg L, Boman G, Böttiger LE, et al. Adverse reactions to nitrofurantoin. Analysis of 921 reports. Am J Med 1980; 69:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goemaere NN, Grijm K, van Hal PT, den Bakker MA. Nitrofurantoin-induced pulmonary fibrosis: a case report. J Med Case Rep 2008; 2:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Livanios K, Karampi ES, Sotiriou A, et al. Nitrofurantoin-induced acute pulmonary toxicity. Respirol Case Rep 2016; 4:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baptista JP, Casanova PC, Sousa JP, et al. [Acute eosinophilic pneumonia associated with acute respiratory distress syndrome: case report]. Rev Port Pneumol 2004; 10:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brutinel WM, Martin WJ 2nd. Chronic nitrofurantoin reaction associated with T-lymphocyte alveolitis. Chest 1986; 89:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lentz RJ, Argento AC, Colby TV, et al. Transbronchial cryobiopsy for diffuse parenchymal lung disease: a state-of-the-art review of procedural techniques, current evidence, and future challenges. J Thorac Dis 2017; 9:2186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner RD, Barber CM. Relapsing nitrofurantoin-induced pneumonitis. Respir Med Case Rep 2012; 5:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheehan RE, Wells AU, Milne DG, Hansell DM. Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities. J Comput Assist Tomogr 2000; 24:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bidad K, Harries-Jones R. Nitrofurantoin lung injury. Age Ageing 2004; 33:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fux R, Mörike K, Gleiter CH. [Unwanted side effects of antibacterials--a diagnostic challenge]. Dtsch Med Wochenschr 2008; 133:F4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weir M, Daly GJ. Lung toxicity and Nitrofurantoin: the tip of the iceberg? QJM 2013; 106:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mullerpattan JB, Dagaonkar RS, Shah HD, Udwadia ZF. Fatal nitrofurantoin lung. J Assoc Physicians India 2013; 61:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kochhar S, Bommu VJL, Kocur M, et al. A Unique Interaction of Methotrexate and Nitrofurantoin Resulting in Irreversible Pulmonary Fibrosis. Cureus 2022; 14:e20892.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4371 Version 22.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16212142" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Chronic nitrofurantoin-induced lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7308333" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Pulmonary reactions to nitrofurantoin. 447 cases reported to the Swedish Adverse Drug Reaction Committee 1966-1976.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/841294" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Nitrofurantoin-induced acute, subacute and chronic pulmonary reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27100576" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Evaluation of the Risk of Nitrofurantoin Lung Injury and Its Efficacy in Diminished Kidney Function in Older Adults in a Large Integrated Healthcare System: A Matched Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25747822" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Nitrofurantoin-induced pulmonary toxicity: A case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26066581" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2766810" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Hospitalizations for pulmonary reactions following nitrofurantoin use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15316202" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Interstitial lung disease induced by drugs and radiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19339098" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : [Rapid resolution of nitrofurantoin-induced interstitial lung disease].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21407041" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Nitrofurantoin-induced desquamative interstitial pneumonitis in a 7-year-old child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17972973" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Nitrofurantoin-induced interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19902831" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Poor medication history plus slow symptom onset delays a diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17655981" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : [Nitrofurantoin-induced lung disease: about two cases].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6571582" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Nitrofurantoin-induced interstitial pulmonary fibrosis. Presentation and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7031172" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Nitrofurantoin pulmonary toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5700010" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Chronic nitrofurantoin pulmonary reaction. Report of 5 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10679548" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Bronchiolitis obliterans organising pneumonia associated with the use of nitrofurantoin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16538151" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Drug-associated organizing pneumonia: high-resolution CT findings in 9 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18818785" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Nitrofurantoin-associated bronchiolitis obliterans organizing pneumonia: report of a case.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22479089" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Nitrofurantoin-induced pulmonary reaction involving respiratory symptoms: case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17495377" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Severe nitrofurantoin lung disease resolving without the use of steroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18392467" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Chronic eosinophilic pneumonia secondary to long-term use of nitrofurantoin: high-resolution computed tomography findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/798484" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Desquamative interstitial pneumonia following long-term nitrofurantoin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8234222" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : [Pulmonary toxicity caused by nitrofurantoin].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/464388" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Acute pulmonary injury in rats by nitrofurantoin and modification by vitamin E, dietary fat, and oxygen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17678542" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Concomitant pulmonary and hepatic toxicity secondary to nitrofurantoin: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17519837" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Nitrofurantoin-induced lung- and hepatotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35979248" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Concomitant Nitrofurantoin-Induced Autoimmune Hepatitis and Interstitial Lung Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16718946" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Recurrent acute nitrofurantoin-induced pulmonary toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25348483" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Sub-acute cutaneous lupus erythematosus following nitrofurantoin: causative or coincidental?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25935915" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Rare adverse effect of a common drug: nitrofurantoin-induced ANCA-associated vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10334121" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Nitrofurantoin-induced immune-mediated lung and liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7435512" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Adverse reactions to nitrofurantoin. Analysis of 921 reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18495029" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Nitrofurantoin-induced pulmonary fibrosis: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26839698" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Nitrofurantoin-induced acute pulmonary toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15492880" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : [Acute eosinophilic pneumonia associated with acute respiratory distress syndrome: case report].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3484445" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Chronic nitrofurantoin reaction associated with T-lymphocyte alveolitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28840020" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Transbronchial cryobiopsy for diffuse parenchymal lung disease: a state-of-the-art review of procedural techniques, current evidence, and future challenges.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26056860" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Relapsing nitrofurantoin-induced pneumonitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10752888" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15226112" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Nitrofurantoin lung injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19097002" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : [Unwanted side effects of antibacterials--a diagnostic challenge].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22836192" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Lung toxicity and Nitrofurantoin: the tip of the iceberg?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24772739" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Fatal nitrofurantoin lung.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35145797" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A Unique Interaction of Methotrexate and Nitrofurantoin Resulting in Irreversible Pulmonary Fibrosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
